30 articles tagged with #drug-discovery. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
AI × CryptoBullishCrypto Briefing · Mar 267/10
🤖Metanova Labs is revolutionizing drug discovery by using Bittensor's decentralized AI network to screen billions of molecules efficiently. The platform utilizes combinatorial reactions to expand screening possibilities to 65 billion compounds and implements dual incentive mechanisms to drive innovation in pharmaceutical research.
$TAO
AIBullisharXiv – CS AI · Mar 117/10
🧠Researchers introduce Logos, a compact AI model that combines multi-step logical reasoning with chemical consistency for molecular design. The model achieves strong performance in structural accuracy and chemical validity while using fewer parameters than larger language models, and provides transparent reasoning that can be inspected by humans.
AIBullisharXiv – CS AI · Mar 57/10
🧠Researchers have introduced Mozi, a dual-layer architecture designed to make AI agents more reliable for drug discovery by implementing governance controls and structured workflows. The system addresses critical issues of unconstrained tool use and poor long-term reliability that have limited LLM deployment in pharmaceutical research.
AIBullisharXiv – CS AI · Mar 57/10
🧠Researchers introduce MMAI Gym for Science, a training framework for molecular foundation models in drug discovery. Their Liquid Foundation Model (LFM) outperforms larger general-purpose models on drug discovery tasks while being more efficient and specialized for molecular applications.
AIBullisharXiv – CS AI · Mar 56/10
🧠Researchers developed a new AI-powered framework for crystal structure prediction that uses large language models and symmetry-driven generation to overcome computational bottlenecks. The approach achieves state-of-the-art performance in discovering new materials without relying on existing databases, potentially accelerating materials science research.
AIBullisharXiv – CS AI · Mar 47/102
🧠Researchers developed RxnNano, a compact 0.5B-parameter AI model for chemical reaction prediction that outperforms much larger 7B+ parameter models by 23.5% through novel training techniques focused on chemical understanding rather than scale. The framework uses hierarchical curriculum learning and chemical consistency objectives to improve drug discovery and synthesis planning applications.
$ATOM
AIBullisharXiv – CS AI · Mar 46/103
🧠Researchers developed a Neuro-Symbolic Agentic Framework combining machine learning with LLM-based reasoning to predict colorectal cancer drug responses. The system achieved significant predictive accuracy (r=0.504) and introduces 'Inverse Reasoning' for simulating genomic edits to predict drug sensitivity changes.
AIBullisharXiv – CS AI · Mar 37/103
🧠Researchers developed mCLM, a 3-billion parameter modular Chemical Language Model that generates functional molecules compatible with automated synthesis by tokenizing at the building block level rather than individual atoms. The AI system outperformed larger models including GPT-5 in creating synthesizable drug candidates and can iteratively improve failed clinical trial compounds.
AIBullisharXiv – CS AI · Mar 37/103
🧠Researchers have developed FROGENT, an AI multi-agent system that uses large language models to automate the entire drug discovery pipeline from target identification to synthesis planning. The system outperformed existing AI approaches across eight benchmarks and demonstrated practical applications in real-world drug design scenarios.
AIBullishGoogle DeepMind Blog · Nov 257/102
🧠AlphaFold has significantly accelerated scientific research and biological discovery over the past five years. The AI system has enabled breakthroughs in protein structure prediction, fueling innovation across the global scientific community.
AIBullishGoogle DeepMind Blog · Oct 237/103
🧠Google has launched a new 27 billion parameter foundation model for single-cell analysis, built on the Gemma family of open models. The model has reportedly helped discover a new potential cancer therapy pathway, demonstrating practical medical applications of AI technology.
AIBullishGoogle DeepMind Blog · Oct 97/105
🧠Demis Hassabis and John Jumper have been awarded the Nobel Prize in Chemistry for developing AlphaFold, an AI system that predicts 3D protein structures from amino acid sequences. This recognition highlights the transformative impact of AI in scientific research and drug discovery.
AINeutralarXiv – CS AI · Mar 166/10
🧠Researchers introduce Budget-Sensitive Discovery Score (BSDS), a formally verified framework for evaluating AI-guided scientific candidate selection under budget constraints. Testing on drug discovery datasets reveals that simple random forest models outperform large language models, with LLMs providing no marginal value over existing trained classifiers.
AIBearisharXiv – CS AI · Mar 96/10
🧠A comprehensive evaluation of Boltz-2, an AI-based drug discovery tool, reveals significant limitations in predicting protein-ligand binding structures and affinities. The study found only weak correlations with physics-based methods and concluded that while useful for initial screening, Boltz-2 lacks the precision required for reliable drug lead identification.
AIBullisharXiv – CS AI · Mar 36/108
🧠Researchers introduce MicroVerse, a specialized AI video generation model for microscale biological simulations, addressing limitations of current video generation models in scientific applications. The work includes MicroWorldBench benchmark and MicroSim-10K dataset, targeting biomedical applications like drug discovery and educational visualization.
AIBullisharXiv – CS AI · Mar 37/107
🧠Researchers introduce MERA (Multimodal Mixture-of-Experts with Retrieval Augmentation), a new AI framework for protein active site identification that addresses challenges in drug discovery. The system achieves 90% AUPRC performance on active site prediction through hierarchical multi-expert retrieval and reliability-aware fusion strategies.
AIBullisharXiv – CS AI · Mar 36/107
🧠Researchers developed a pharmacology knowledge graph for drug repurposing and found that removing chemical structure representations improved performance while dramatically reducing computational requirements. The study showed that drug behavior can be accurately predicted using only target protein information and network topology, with larger datasets proving more valuable than complex models.
AIBullisharXiv – CS AI · Mar 37/107
🧠Researchers introduce DeMol, a new dual-graph framework for molecular property prediction that explicitly models both atoms and chemical bonds to achieve superior accuracy. The approach addresses limitations of conventional atom-centric models by incorporating bond-level phenomena like resonance and stereoselectivity, establishing new state-of-the-art results across multiple benchmarks.
$ATOM
AIBullisharXiv – CS AI · Mar 37/106
🧠Researchers introduce MultiPUFFIN, a multimodal AI foundation model that predicts molecular properties for drug discovery and materials science. The model combines multiple data types and thermodynamic principles to achieve superior performance while using 2000x fewer training molecules than existing models like ChemBERTa-2.
AIBullisharXiv – CS AI · Mar 36/106
🧠Researchers introduce GlassMol, a new interpretable AI model for molecular property prediction that addresses the black-box problem in drug discovery. The model uses Concept Bottleneck Models with automated concept curation and LLM-guided selection, achieving performance that matches or exceeds traditional black-box models across thirteen benchmarks.
AIBullisharXiv – CS AI · Mar 36/104
🧠Researchers propose a new iterative distillation framework for fine-tuning diffusion models in biomolecular design that optimizes for specific reward functions. The method addresses stability and efficiency issues in existing reinforcement learning approaches by using off-policy data collection and KL divergence minimization for improved training stability.
AIBullisharXiv – CS AI · Mar 27/1019
🧠Researchers have developed VCWorld, a new AI-powered biological simulation system that combines large language models with structured biological knowledge to predict cellular responses to drug perturbations. The system operates as a 'white-box' model, providing interpretable predictions and mechanistic insights while achieving state-of-the-art performance in drug perturbation benchmarks.
AIBullisharXiv – CS AI · Mar 26/1014
🧠Researchers have developed GenAI-Net, a generative AI framework that automates the design of chemical reaction networks (CRNs) for synthetic biology applications. The system can automatically generate biomolecular circuits for various functions including logic gates, oscillators, and classifiers, potentially accelerating the development of biomanufacturing and therapeutic technologies.
AIBullishIEEE Spectrum – AI · Feb 46/104
🧠Google DeepMind has launched AlphaGenome, an AI tool that analyzes the 98% of human DNA that doesn't code for proteins but regulates gene expression. The deep-learning platform can predict 11 types of biological signals and is already being used by thousands of scientists worldwide for cancer research, drug discovery, and synthetic DNA design.
$LINK$NEAR
AIBullishGoogle DeepMind Blog · Nov 256/106
🧠AlphaFold, Google DeepMind's AI protein structure prediction system, has successfully revealed the structure of a key protein associated with heart disease. This breakthrough demonstrates AI's growing capability in medical research and drug discovery applications.
